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Abstract
Joint degeneration observed in the rat monoiodoacetate (MIA) model of osteoarthritis shares many histological features
with the clinical condition. The accompanying pain phenotype has seen the model widely used to investigate the
pathophysiology of osteoarthritis pain, and for preclinical screening of analgesic compounds. We have investigated the
pathophysiological sequellae of MIA used at low (1 mg) or high (2 mg) dose. Intra-articular 2 mg MIA induced expression of
ATF-3, a sensitive marker for peripheral neuron stress/injury, in small and large diameter DRG cell profiles principally at levels
L4 and 5 (levels predominated by neurones innervating the hindpaw) rather than L3. At the 7 day timepoint, ATF-3 signal
was significantly smaller in 1 mg MIA treated animals than in the 2 mg treated group. 2 mg, but not 1 mg, intra-articular
MIA was also associated with a significant reduction in intra-epidermal nerve fibre density in plantar hindpaw skin, and
produced spinal cord dorsal and ventral horn microgliosis. The 2 mg treatment evoked mechanical pain-related
hypersensitivity of the hindpaw that was significantly greater than the 1 mg treatment. MIA treatment produced weight
bearing asymmetry and cold hypersensitivity which was similar at both doses. Additionally, while pregabalin significantly
reduced deep dorsal horn evoked neuronal responses in animals treated with 2 mg MIA, this effect was much reduced or
absent in the 1 mg or sham treated groups. These data demonstrate that intra-articular 2 mg MIA not only produces joint
degeneration, but also evokes significant axonal injury to DRG cells including those innervating targets outside of the knee
joint such as hindpaw skin. This significant neuropathic component needs to be taken into account when interpreting
studies using this model, particularly at doses greater than 1 mg MIA.
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Introduction
Osteoarthritis (OA) is one of the most prevalent sources of
chronic pain, affecting around 10% of men and 20% of women
aged 60+ worldwide [1]. The disabling effect of osteoarthritis is
not simply due to altered joint biomechanics, such as locking and
crepitation, but also evoked and spontaneous pain associated with
the arthritic joint [2]. Current analgesics are relatively ineffective
and are associated with various gastrointestinal, cardiac and renal
adverse effects [3].
The monoiodoacetate model of OA, in which a single injection of
the irreversible NADPH inhibitor, sodium monoiodoacetate (MIA),
is made into the joint space, provides a model of the painful and
structural components of OA in rodents. The doses most frequently
used are 1, 2 or 3 mg [4,5,6], with the model usually assessed up to
14 days post-induction, with some studies extending further to 30,
56 or 68 days [5,7,8]. MIA has been shown to inhibit chondrocyte
metabolism, precipitating a rapid degeneration of joint integrity
with features mirroring those seen clinically [5]. These include
synovial thickening, loss of cartilage, formation of osteophytes and
eventual fibrillation of cartilage. The inflammatory early phase of
the model also features joint swelling and immune cell infiltration of
the patellar fat pad, and resolves fully by day 7 [9,10].
In parallel to degenerative changes within the joint, a pain
phenotype rapidly develops in the hindlimb ipsilateral to the
injected knee, suggesting the presence of central sensitization. This
phenotype has been assessed using standard behavioural measures
of evoked pain, including mechanical and thermal stimuli applied
to an area of referred pain on the hindpaw, as well as calibrated
pressure and torque applied to the knee [8,11,12]. Novel measures
employed, intended to gauge movement evoked or ongoing pain,
include tests of motility, weight-bearing, grip strength and sleep
disruption [9,10,12,13,14,15,16,17].
Electrophysiological studies have demonstrated peripheral
changes in the excitability of knee joint afferents as well as central
changes in the evoked responses and pharmacological manipula-
tion of deep dorsal horn neurones with receptive fields in the
hindpaw ipsilateral to joint degeneration [11,18,19]. These deep
dorsal horn neurones are subject to increased 5-HT3R activity
and increased endocannabinoidergic tone [18,19].
While pregabalin, an analgesic clinically effective in a variety of
neuropathic conditions [20], has only minimal effectiveness on
deep dorsal horn neuronal evoked responses in sham animals, it is
able to significantly reduce responses in MIA animals [19]. A
similar state-dependency is seen in the action of a related drug
with a similar mechanism of action, gabapentin, which is more
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evoked central sensitization in human subjects [21].
MIA has been shown to evoke ATF-3 expression in DRG cells,
which was suggested to represent damage to joint afferents [22].
Pain related hypersensitivity in this model has therefore been
attributed to inflammation and degenerative changes within the
knee joint, as well as a possible localised neuropathic component
involving joint afferents.
Here we have characterised the expression of ATF-3 (a marker
of neuronal injury), peripheral innervation and spinal microgliosis
following MIA treatment of rats up to 14 days after model
induction. We demonstrate significantly increased expression of
ATF-3, primarily in L4 and L5 DRG, after intraarticular injection
of 2 mg, but not 1 mg MIA. ATF-3 upregulation in the 2 mg MIA
model is associated with reduced intraepidermal nerve fibre
(IENF) innervation of ipsilateral plantar hindpaw skin, spinal
microgliosis and greater hindpaw mechanical hypersensitivity,
indicating a significant neuropathic component at this dose which
includes afferents innervating territories outside of the knee joint.
Additionally, while deep dorsal horn evoked responses are reduced
by pregabalin in the 2 mg MIA model, the effects of the drug are
significantly less pronounced where arthritis has been induced by
1 mg MIA.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the UK Home
Office (project license 1205) and follow the guidelines of the
International Association for the Study of Pain [26].
Animal care and model induction
Male Sprague-Dawley rats (Central Biological Services, Uni-
versity College London) weighing 120–140 g at the time of
induction were used. Animals were anaesthetised using isofluorane
and a single injection of 25 ul sterile 0.9% saline containing 2 mg
or 1 mg of monosodium iodoacetate (MIA, Sigma, UK) was
administered through the left patellar tendon using a 27G needle.
Sham injections used ipsilateral saline only, and were assessed
histologically at day 7, except for articular histology, which used
contralateral saline and was assessed at day 14.
Behaviour
Behaviour was assessed at 3, 7 and 14 days following MIA
injection. Testing was preceded by a 30-min acclimatisation
period. Cooling hypersensitivity was assessed using a drop of
acetone applied to the plantar surface of the hind paws, both
ipsilateral and contralateral to the injected knee. A marked,
delayed, flinching or shaking behaviour was a positive outcome.
The test was repeated a total of five times on each side with a
minimum of 5 min between each application. The resulting score
was doubled to give a score out of 10, allowing plotting on the
same axes as mechanical hypersensitivity. Mechanical hypersen-
sitivity was assessed by applying 1, 6 and 8 g von Frey filaments,
(Touch-test, North Coast Medical Inc., San Jose CA, USA) 5 times
to the plantar surface proximal to the digits, and 5 times to the toes
of the ipsilateral and contralateral hind paws. Withdrawal
responses and whole paw lifts elicited by von Frey hairs were
scored as positive, with a Mean Difference Score of ipsilateral –
contralateral withdrawals used for graphing and statistical analysis,
which used Kruskall-Wallis test with Dunn’s or Bonferroni’s
multiple comparison test for timecourse and between group
comparisons respectively.
Weight bearing was assessed using an incapacitance tester
(Linton Instrumentation, Norfolk, UK). Rats were placed in a
plexiglass enclosure so that each hindpaw rested on a separate
weighing plate. After 2 minutes’ habituation, the force exerted by
each hind paw was measured over a 5s testing period. The first 3
sets of 5s measurements were taken and then averaged. These
values were then transformed to give the percentage of total
hindlimb weight borne on the ipsilateral side. Data were analyzed
using One-way ANOVA or 2-way ANOVA with Bonferroni’s
Multiple Comparison test for time course and between group
comparisons respectively.
Experimenters were blinded to treatment groups where saline or
different doses of MIA were used.
Immunohistochemistry
Animals were terminally anaesthetised and transcardially
perfused with chilled 4% paraformaldehyde in 0.1% phosphate
buffer. Lumbar spinal cord was dissected out with ipsilateral and
contralateral L3, L4 and L5 DRG and proximal sciatic nerves
attached. For nerve morphometry studies, the sciatic nerve was
followed until it branched into the tibial, common peroneal and
sural nerves posterior to the knee joint (the tibial nerve includes the
posterior articular nerve that innervates the articular structures).
5 mm samples were taken from each branch, proximal to the knee
joint. Additional 5 mm samples were taken from the common
peroneal nerves 10 mm distal to the knee joint. Skin biopsies were
taken from the hindpaw glabrous skin proximal to the pad below
the first digit, taking the full width of the plantar surface.
Tissues were postfixed in 4% paraformaldeyde for 2 hours at
room temperature then transferred into 20% sucrose overnight at
4uC [27]. Tissue was embedded in OCT and stored at 280uC.
Transverse sections of skin were cut at 14 mm on a cryostat onto
chrome alum gelatin-covered slides. DRG and transverse spinal
cord sections were cut at 10 mm on a cryostat onto SuperFrost
Ultra Plus slides.
Nerves were postfixed in 3% glutaraldehyde at 4uC overnight,
washed in 0.1 M PB, osmicated, dehydrated, and embedded in
epoxy resin (TAAB Embedding Materials). 1 mm sections were cut
on an ultramicrotome and stained with toludine blue.
After overnight postfixation in 4% PFA, knee joints were
dissected to remove muscle and tranferred into a decalcifying
buffer comprising 7% AlCl3, 5% formic acid, and 8.5% HCl for
10 hours at 4uC, before being washed in 0.1 M phosphate buffer,
pH7.2. processed and embedded in paraffin wax. 6 mm sagittal
sections from each condyle were cut and mounted onto
microscope slides, then dried at 60uC overnight. After dewaxing
and rehydrating, sequential sections were stained using Toluidine
blue pH4 to visualize proteoglycans in the articular cartilage.
DRG cells were visualized by immunostaining with antibodies
raised against bIIITubulin (Promega, mouse monoclonal, 1:800)
and ATF-3 (Santa Cruz, rabbit polyclonal, 1:400). Intra-epidermal
nerve fibres (IENF) in skin biopsies were visualized with the pan-
neuronal marker protein gene product (PGP), polyclonal rabbit
PGP9.5 (Ultraclone, 1:800). Spinal cord microglia were visualized
using rabbit anti-Iba1 (WAKO, 1:1000). Secondary antibodies
used were anti-rabbit Cy3 (Stratech; 711-166-152; 1:500; 2.5 hr)
and AlexaFluor 488 anti-mouse (Invitrogen, 1:1000, 2.5 hr).
Overnight incubation of primary antibodies was preceded by
incubation with normal donkey serum (Millipore Bioscience
Research Reagents; S30; 1:10; 30 min). All reagents were diluted
in PBS/0.2% Triton X-100/0.1% sodium azide.
Immunofluorescence was visualized under a Zeiss Imager.Z1
microscope.
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DRG were randomly selected from each animal. Both ATF-3
+
and the total BIIITub
+ nucleated cell profile populations were
counted and their diameters measured to determine cell size
distribution. Because on sectioning DRG cells will be cut into
multiple profiles we refer to DRG cell profiles and not absolute
DRG cell numbers when discussing quantification of ATF-3
expression. Cell counting and analysis was performed using
AxioVision LE, release 4.2.
Epidermal fibers were counted at 406magnification live on the
microscope according to rules set out by Lauria et al. [28]. Only
nerve fibers that could be seen to cross the basement membrane
between the epidermis and dermis were counted. Four skin
sections were counted per animal, by a blinded experimenter. The
length of the epidermis sample in mosaic-photomicrograph was
measured using ImageJ and the intraepidermal nerve fiber density
(IENFD) calculated as number of fibers per millimeter. Data were
analyzed using paired t-test of ipsilateral vs contralateral IENF
density, or unpaired t-test of 2 mg vs 1 mg IENF ipsilateral density
as a percentage of contralateral density.
Quantification of the number and morphology of Iba1
immunoreactive microglia in the spinal cord was performed in
four sections of spinal cord at the level of L4 per animal. Microglia
were quantified within 4 defined 10,000 um
2 areas in the
superficial dorsal horn or ventral horn. Microglia in which process
length was less than double the soma diameter were classified as
presenting an effector morphology, while microglia in which
process length was more than double soma diameter were defined
as possessing surveyor morphology, a method used previously by
[29]. Cells were sampled only if the nucleus was visible within the
plane of section and if cell profiles exhibited distinctly delineated
borders. Spinal cord ATF-3 staining was quantified as the total
number of ATF-3
+ profiles present in 4 spinal cord sections per
animal.
Knee joint sections were imaged using an Epson perfection
V700 photo flatbed scanner at 3200 dpi. Cartilage proteoglycan
content was scored on a scale of 0–4 where 0=no loss of cartilage
proteoglycan staining relative to a normal control, 1=minimal
loss, 2=mild loss, 3=moderate loss and 4=total loss of
proteoglycan staining. The extent of cartilage proteoglycan loss
was assessed as 1/3, 2/3 or 3/3 of the condylar surfaces and the
above score was multiplied by 1, 2 or 3, respectively to give a
maximum score of 12 for total loss over the whole surface [30].
For articular histology only, ipsilateral MIA treated knees were
compared to contralateral saline-injected knees.
In all cases, quantification was performed by a single, blinded
observer. Unless stated otherwise, data were analysed using One-
way ANOVA with Dunnett’s or Bonferroni’s multiple comparison
test for timecourse or between-group comparisons respectively.
Electrophysiology
Two weeks after MIA injection (post-operative days 15–19), in
vivo electrophysiological studies were performed as previously
described [31]. Briefly, animals were anesthetized and maintained
for the duration of the experiment with isofluroane (1.5–1.7%)
delivered in a gaseous mix of N2O (66%) and O2 (33%). A
laminectomy was performed to expose the L4–5 segments of the
spinal cord. Extracellular recordings were made from ipsilateral
deep dorsal horn neurones (laminae V–VI) using parylene coated
tungsten electrodes (A–M Systems, USA). The neurones included
in this study met the following criteria: they had a receptive field
on the plantar hindpaw; they all responded with at least 50 spikes
to both light touch (8 g von frey) and noxious stimuli (60 g von
Frey and 48uC heat); they responded to natural stimuli in a graded
manner with coding of increasing intensity; they exhibited windup
when repeatedly stimulated; and they were situated at a depth of
.500 mm from the surface of the spinal cord.
A train of 16 transcutaneous electrical stimuli (2 ms wide pulses,
0.5 Hz) applied at 3 times the threshold current for C-fibre activation
of the dorsal horn cell was delivered via stimulating electrodes
inserted into the peripheral receptive field in the hindpaw. A post-
stimulus time histogram was constructed such that responses evoked
via Ab – (0–20 ms), Ad – (20–90 ms) and C-fibres (90–350 ms) were
separated and quantified on the basis of latency. Responses occurring
after the C-fibre latency band were taken to be the post-discharge
(repetitive firing) of the WDR cell (350–800 ms).
The centre of the peripheral receptive field was also stimulated
using punctate mechanical and thermal stimuli (2, 8, 26 and 60 g
von Frey filaments and a water jet applied at 35, 40, 45, and
48uC). Application of each von Frey hair was separated by a
minimum interval period of 50 seconds. All natural stimuli were
applied for a period of 10 seconds per stimulus. Data was captured
and analysed by a CED 1401 interface coupled to a computer
running Spike 2 software (Cambridge Electronic Design; PSTH
and rate functions).
Pharmacological assessment was carried out on one ipsilateral
neuron only per animal. One round of testing was performed
every twenty minutes, and consisted of a train of electrical stimuli
followed by graded natural stimuli as described above. Following
three consecutive stable control trials (,10% variation for the C-
fibre evoked response) neuronal responses were averaged to give
the pre-drug control values.
Pregabalin (a gift from Pfizer, Sandwich, UK) was dissolved in
0.9% saline solution at a concentration of 10 mg/kg, and
administered via subcutaneous injection in the scruff of the back
of the neck. Previous studies indicated that this concentration
significantly reduced spinal neurone evoked responses in 2 mg
MIA treated, but not sham injected, rats [19]. The effect of the
drug was followed for an hour, with tests carried out at 10, 30 and
50 minutes after dosing. The value of greatest change from the
baseline for each metric (electrical stimuli, natural stimuli) was
then found and expressed as a percentage of the predose baseline,
and plotted to allow comparison of drug effect in sham, 1 mg MIA
and 2 mg MIA animals. Kruskal-Wallis tests with Dunn’s posttest
were used to compare drug effect for each metric. The sham and
2 mg data is included for comparison, but has previously been
published in a different form [19].
Results
Pain behaviour and cartilage loss following intra-articular
MIA treatment
Arthritis-associated referred pain behaviours were assessed at
the hindpaw as previously described [13]. Significant hypersensi-
tivity to von Frey hair application and acetone cooling were both
observed by day 3 in 2 mg and 1 mg MIA animals (Figure 1A
Kruskal Wallis test, P,0.05 vs preinjection baseline, n=12
animals/group). Significant weight bearing difference between
ipsilateral and contralateral hindlimb was seen following 2 mg and
1 mg MIA injection (Fig. 1B, One-way ANOVA with Dunnett’s
multiple comparison test, P,0.05, n=12 animals/group). There
was no hypersensitivity on the contralateral hindpaw. Consistent
with previous studies, the timecourse of weightbearing asymmetry
is biphasic, with asymmetry slightly correcting at the 7d timepoint
but returning at 14d [6,10]. The weight-bearing alteration in the
2 mg group was not significantly different to that in the 1 mg
group (2-way ANOVA with Bonferroni’s post test, n=12 animals/
group, P.0.05 at all time points).
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significantly less mechanical hypersensitivity in the 1 mg group,
with significantly fewer withdrawals to the 8 g von Frey hair at all
time points compared to the 2 mg group (Fig. 1A, Kruskal Wallis
test with Bonferroni’s posttest, P,0.05). No significant difference
between 1 mg and 2 mg groups was apparent in the response to
acetone cooling or weight bearing at any timepoint.
Despite the difference in evoked behaviour, the extent of
articular cartilage proteogylcan loss at 14d was not significantly
different in 2 mg (Fig. 1C) vs 1 mg (Fig. 1D) groups (Table S1),
consistent with existing data at this time point [32]. Note that, after
the 7d MIA stage, there is no significant inflammation in the joint
structures [9]. Because the degree of cartilage loss could not
explain the difference in mechanical hypersensitivity when
comparing the 2 and 1 mg dose of MIA at day 14, we went on
to assess the extent of peripheral neural injury.
Increased ATF-3 expression within DRG cells and
motoneurones following MIA application
The expression of the transcription factor ATF-3 is a sensitive
marker of neuronal insult or injury. It is expressed in DRG cells
and spinal cord ventral horn motoneurons within 3d days
following axotomy or crush, remaining positive for at least 28
days after nerve injury [33,34]. Immunohistochemistry for ATF-3
and BIIITub positive cell profiles in the DRG enabled
approximation of the percentage of total DRG cell nuclear
profiles immunopositive for ATF-3 at the level of L3, L4 and L5 3,
7 and 14 days after MIA injection (Figure 2, illustrated and
quantified as % of DRG in Figure 3A). Analysis of cell size
distribution showed ATF-3 expression was not restricted to one
population of cells but rather present in small, medium and large
cell profiles.
The total mean ATF-3 signal peaked at 20.83% of nucleated
profiles quantified in L4 at day 7 (Fig. 3D). Total mean ATF-3 signal
was below 5% in L3 at all time points. No ATF-3 positive nuclear
profiles were present in L2 and L6 DRG (data not shown). Sham
injection of saline did not induce significant ATF-3 expression at any
of the levels assessed at day 7, though ATF-3 expression in naı ¨ve
DRG was observed very infrequently (Figure 3C, D, in ,1% of
profiles counted). ATF-3 expression was significantly greater at 7 and
14 days after MIA injection compared to 7d sham in L4 (Figure 3D,
One-way ANOVA with Dunnett’s multiple comparison test,
n=9 67d sham, 1267d MIA, 7614d MIA), and at 7 days after
injection in L5 (n=1267d, P,0.01).
As expression in the 2 mg group peaked at the 7d timepoint,
this timepoint was chosen to assess ATF-3 expression in the 1 mg
MIA group. ATF-3 expression in 1 mg MIA treated rats
(Figure 3B) was not present at a level significantly greater than
that seen in saline injected sham animals at the 7d timepoint,
although a strong trend was noted. There were significantly fewer
ATF-3
+ profiles in 1 mg (7.6% of L4 DRG) than in 2 mg (20.83%
of L4 DRG) MIA treated animals at the 7 day timepoint
(Figure 3E, 1 way ANOVA with Bonferroni’s multiple comparison
test, n=967d sham, 1262 mg MIA, 1261 mg MIA, 2 mg vs
1m gP ,0.001 at L4, 2 mg vs 1 mg P,0.01 at L5, 7d sham vs
1m gP .0.05 at L4 or L5).
Immunohistochemistry also indicated the presence of ATF-3
positive nuclei in ventral horn motor neurones of 2 mg MIA
treated animals (Figure S1). The absolute number of these ATF-3
positive nuclei was small (mean of 1.2 ATF-3
+ cells per section of
Figure 1. Behavioural and articular histological assessment of MIA animals. A – withdrawals in response to 1 g, 6 g or 8 g von frey hair or
acetone applied to the plantar hindpaw 3, 7 or 14 days after intra-articular saline, 2 mg or 1 mg MIA injection (Kruskal Wallis test of: timecourse,
P,0.05 +,P ,0.01 ++,P ,0.001 +++ vs preinjection baseline; inter-group comparison P,0.05 *, P,0.01 ** n=12 animals/group). B – incapacitance
testing of 2 mg or 1 mg MIA treated animals at 3, 7 and 14d after treatment (2-way ANOVA with Bonferroni’s post test, n=12 animals/group. P.0.05
at all time points). C – 2 mg MIA treated rat knee sagittal sections from day 14, stained with toluidine blue to visualise cartilage proteoglycan content.
Fem=femoral condyl, Tib=tibial condyl. Ant=anterior aspect of knee, Post=posterior aspect. D – 1 mg MIA rat knee sections from day 14. E – saline
injected contralateral control knee from day 14.
doi:10.1371/journal.pone.0033730.g001
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day 7 (one-way ANOVA with Dunnett’s multiple comparison test,
n=8 animals per timepoint, p,0.05). ATF-3 positive ventral horn
nuclear profiles were not present in the 1 mg MIA or 7d sham
treated groups.
The cell bodies of afferent fibres innervating the joint reside in
primarily L3 and L4 DRG [35], and comprise below 5% of the
total cell bodies in the DRG at these levels [36]. As the magnitude
of ATF-3 expression observed in L5 DRG could not arise purely
from joint afferents, we studied nerve morphometry as well as
primary afferent terminations within hindpaw plantar epidermis.
Intra-articular MIA is associated with a reduction in
ipsilateral hindpaw intra-epidermal nerve fibre density
Because the sciatic nerve branches into the tibial, peroneal and
sural nerves posterior to the knee joint we examined toluidine blue
stained semithin sections of these nerves (Figure S2). There was no
evidence of structural degeneration, demyelination, inflammatory
infiltrate or any other difference between ipsilateral and
contralateral samples at any of the sites assessed at day 7 following
2 mg MIA induction.
To investigate the possibility of a ‘dying back’ small fibre
neuropathy, intra-epidermal nerve fibre density (IENFD) was
quantified in the hindpaw. This measure is often used clinically
and experimentally [27,37] to assess small fibre integrity in
peripheral neuropathies. PGP9.5 immunoreactive IENFs were
quantified in skin sections from the ipsilateral and contralateral
plantar hindpaw in a blinded fashion (Figure 4A, B). 2 mg MIA
induction was associated with a significant decrease in ipsilateral
IENFD of 26% at day 7 and 37% at day 14 (Figure 4C, paired t-
test of ipsi vs contralateral density, n=867d, 4614d, P,0.05).
In 1 mg MIA treated rats there was no evidence of ipsilateral
reduction in IENFD (P.0.05 vs contra side, paired t test). The
ipsilateral IENFD was significantly higher than the ipsilateral 2 mg
IENF density at the same time point (unpaired t test, P,0.01,
n=8 67d 2 mg, 467d 1 mg).
Intra-articular MIA is associated with spinal microgliosis
In a wide range of models, nerve injury is associated with increased
numbers of microglia within the spinal cord [38,39]. Treatment with
intra-articular MIA at a dose of 2 mg resulted in microgliosis within
both the dorsal and ventral horn as demonstrated by immunohis-
tochemistry for the microglial marker Iba1 (Figure 5A). Sham rats,
which received intra-articular saline, had no microgliosisat day 7 and
were indistinguishable from naives. Microgliosis produced by 2 mg
MIA treatment was associated with a significant shift to effector
morphometry, both dorsally and ventrally, by day 7 compared to
sham (Figure 5C and D, One-way ANOVA with Dunnett’s multiple
comparison test, n=467d sham, 1162m gM I A ,P ,0.05). In 2 mg
MIA rat ventral horn, cells were observed enwrapping motor
Figure 2. Cell size distribution for BIIITubulin (green bars, left y axis) and ATF-3 (red bars, right y axis) expressing profiles in DRG
L3, L4 and L5 in sham or 2 mg MIA animals 3, 7 and 14 days after injection. n=9 sham, 7 at day 3, 12 at day 7, 7 at day 14.
doi:10.1371/journal.pone.0033730.g002
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most consistent at L4, where quantification was performed. GFAP
immunoreactivity was quantified in each spinal cord quadrant to
assess astrogliosis, but showed no significant change (data not shown).
As iba-1 reactivity peaked at the 7d timepoint, this timepoint
was selected to assess 1 mg MIA group microglial activity.
Following 1 mg treatment the total number of microglia counted
was not significantly greater than in saline injected 7d sham
animals, and was significantly less than the count in 2 mg MIA rat
dorsal horn (Figure 5B). Although there was a trend for increased
change in morphology in the 1 mg group, this was not significant
(Figure 5E, One-way ANOVA with Bonferroni’s multiple
comparison test, n=467d sham, 1162 mg MIA, 861 mg MIA,
P.0.05 1 mg vs 7d sham, P,0.05 2 mg vs 1 mg).
Systemic Pregabalin Reduces Deep Dorsal Horn Evoked
Responses in 2 mg, but not 1 mg MIA treated animals
Extracellular action potentials were recorded from deep dorsal
horn neurones with receptive fields on the plantar hindpaw, where
behavioural hyperresponse to normally innocuous stimuli is seen
in MIA animals (as above). These neurones were characterised as
wide dynamic range cells (WDR), in that they gave a graded
response to a wide range of innocuous and noxious mechanical
and thermal stimuli, exhibited windup, and were located in
laminae V–VI of the dorsal horn, as previously described [40].
As shown previously [19], pregabalin has minor inhibitory
effects on evoked responses in animals that underwent an
intraarticular saline sham injection 14 days before recording
(Figure 6A, B and C black traces show drug effect on electrical,
mechanical and thermal evoked responses, respectively). WDR
cells in animals that received 2 mg MIA were significantly more
sensitive to pregabalin inhibition (Figure 6A, B, C grey dotted
trace). In contrast, pregabalin inhibition in animals that received
1 mg MIA was not significantly different to sham for any of the
evoked responses assessed (Figure 6A, B, C grey solid vs black
traces). Pregabalin inhibited electrically evoked responses in the C
fibre range and 8 g and 60 g evoked mechanical responses to a
significantly greater extent in 2 mg MIA treated animals than in
1 mg treated animals (Figure 6A, B, Kruskal-Wallis test with
Dunn’s post test, n=sham69, 1 mg MIA, 68, 2 mg MIA69).
Figure 3. Approximation of total DRG ATF-3 expression. A, B, C - DRG profiles show nuclear expression of ATF-3 7 days after 2 mg (A) or 1 mg
(B) MIA, but not 14 days after saline sham injection (C). D - Estimated fraction of DRG profiles expressing ATF-3 in 2 mg MIA-treated animals (One-way
ANOVA with Dunnett’s multiple comparison test, n=9614d sham, 763d, 1267d MIA, 7614d MIA, P,0.01 **, P,0.05 *). E - Comparison of ATF-3
expression in 2 mg vs 1 mg MIA injected groups at 7 day timepoint (1 way ANOVA with Bonferroni’s multiple comparison test, n=967d sham,
1262 mg MIA, 1261 mg MIA, P,0.01 ** P,0.001 ***).
doi:10.1371/journal.pone.0033730.g003
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In this study we have carefully characterised the widely used MIA
model of OA in relation to the development of pain related
behaviour,the degree of joint cartilage lossand neural injury, and the
extent of dorsal horn pharmacological plasticity. To summarise, the
higher dose of MIA (2 mg) was associated with greater hindpaw
mechanical hypersensitivity than the lower dose (1 mg) treatment.
However there was no difference in the degree of cartilage
proteoglycan loss. 2 mg, but not 1 mg, MIA produced an increase
in the expression of the injury marker ATF-3 in DRG cells, a
reduction in intra-epidermal nerve fibre density within plantar
epidermis, and ipsilateral spinal cord microgliosis, indicating
significant neural injury. Systemic pregabalin significantly inhibited
deep dorsal horn WDR cell evoked responses in 2 mg MIA treated
animals, but not in 1 mg- or sham treated animals.
In studying pain-related behaviour, previous investigators have
used a range of doses from 1 to 4.8 mg MIA. We elected to use
either 1 or 2 mg, at the lower end of this dose range. Dose-
dependent effects of MIA have been demonstrated for weight-
bearing asymmetry, cartilage biosynthetic processes and bone
density loss [6,10]. These effects tend to plateau quickly at doses
above 1 mg and indeed we found no difference in cartilage
proteoglycan loss comparing 2 and 1 mg MIA; the behavioural
measures of weight-bearing asymmetry and the response to
acetone cooling were also not significantly different. However
mechanical pain related hypersensitivity of the hindpaw was
strikingly increased at the 2 mg versus 1 mg dose.
We used the expression of ATF-3 [33,34] to assess the degree of
injury to peripheral neurons following intra-articular MIA
injection, in order to explore the possibility that differential
degrees of neuronal injury may underlie the differing evoked
behavioural phenotypes in the 1 mg and 2 mg MIA groups. One
previous study has shown increased expression of ATF-3 in
lumbar DRG cells using 1 mg MIA treatment, however these
findings were not expressed in a manner in which it was possible to
gauge the proportion of all DRG cells expressing ATF-3, and
focussed more on timepoints after 14d [22].
There were a number of aspects of the ATF-3 response
indicating that injury following intra-articular MIA is not
restricted to joint afferents. The proportion of DRG cell profiles
expressing ATF-3 was highest in L4 and 5, DRGs which
principally project to the hindpaw, rather than L3 and 4, which
contain the majority of joint afferents [35]. The size of the ATF-3
signal peaked at ,20% of L4/L5 DRG profiles and cannot
therefore have arisen solely from damage to the relatively small
population (4.6%) of DRG intra-articular afferents, although it
may include these afferents [36]. The lower dose of 1 mg MIA was
associated with ATF-3 expression in much lower percentage of
DRG cell profiless (7.6% of L4).
The signal seen in the MIA model could be the result of a direct
action of MIA on the peripheral nerves running adjacent to the
knee, perhaps secondary to leakage of MIA from the intra-
articular space. We are highly experienced in this model and every
effort is made to prevent any leakage of MIA at the time of intra-
articular injection. Retrograde tracers used in MIA rat joint
actually label a smaller proportion of DRG cells compared to
those traced from a normal joint [36] implying that it is not the
case that joint capsule disruption during the course of the model
could cause MIA to diffuse to a more widespread range of tissues.
We do not see any evidence of systemic effects of MIA and the
increased ATF-3 expression was always strictly unilateral, as were
other markers of neuronal injury discussed below. MIA is able to
induce massive Ca
2+ influx in rat peripheral nerve in vitro via
inhibition of metabolism, as well as being cytotoxic to non-
neuronal cells such as astrocytes [41,42].
Intra-articular MIA triggers a vigorous inflammatory response
up to day 5 post-injection, with associated monocyte and
neutrophil infiltration and joint swelling [5,9]. A similar degree
of joint swelling is observed in other inflammatory models of
monoarthritis, meaning that swelling alone is unlikely to account
for the greater ATF-3 signal observed in the MIA model [45]. It
has recently been shown that some algogens, such as formalin and
capsaicin, which strongly activate subsets of primary afferents
when injected into the plantar hindpaw, trigger ATF-3 expression
in DRG cells [43]. This raises the point as to whether
inflammatory mediators released as a consequence of intra-
articular MIA could contribute to increased ATF-3 expression.
Figure 4. Quantification of intrapepidermal nerve fibre density
in plantar hindpaw following MIA treatment. A, B - sections of
naı ¨ve (A) and MIA (B) plantar hindpaw skin containing PGP9.5
immunoreactive intraepidermal nerve fibres (arrows). C – quantification
of IENFs at the 7 and 14 day timepoints (paired t-test of ipsi vs
contralateral density, n=867d, 4614d, P,0.05). IENF density reduction
is not seen in 1 mg MIA animals.
doi:10.1371/journal.pone.0033730.g004
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different models of inflammation all of which are associated with
enhanced pain-related behaviour. But neither intra-plantar
application of Complete Freund’s Adjuvant, antigen induced
arthritis nor collagen-induced arthritis could induce ATF-3
expression above the level of ,2% in lumbar DRG [44,45].
Additionally, although inflammatory measures resolve by day 7
in the MIA model [10] ATF-3 signal is still present at day 14. This
would appear to rule out a link between ATF-3 signal and
inflammation. A further assessment of ATF-3 expression, a well as
the other measures used in this study, at later timepoints such as 28
days after injection, would illuminate whether the pathological
Figure 5. Quantification of microglial activation in spinal cord following MIA treatment. A, B - expression of the microglial marker iba1 in
L4 spinal cord in 2 mg (A) and 1 mg (B) MIA groups. C, D – Quantification of microglia with effector morphology in dorsal (C) and ventral (D) horn (1-
way ANOVA, n=467d sham, 1162 mg MIA, P,0.05 *). E – Comparison of dorsal horn microgliosis in 2 mg vs 1 mg MIA groups at the 7d timepoint
(1-way ANOVA, n=467d sham, 1162 mg MIA, 861 mg MIA, P,0.05 *).
doi:10.1371/journal.pone.0033730.g005
Figure 6. Effect of pregabalin treatment (10 mg/kg s.c.) on evoked responses of deep dorsal horn WDR neurones. A - Electrically
evoked responses in the Aß, Ah and C fibre range, as well as PD (post-discharge/repetitive firing) expressed as % of predose baseline in 2 mg MIA,
1 mg MIA or sham injected animals. B - Mechanically evoked responses expressed as % of predose baseline in 2 mg MIA, 1 mg MIA or sham injected
animals. C - Thermally evoked responses expressed as % of predose baseline in 2 mg MIA, 1 mg MIA or sham injected animals. Note the significantly
greater effectiveness of pregabalin in the 2 mg treated group (normalized post-drug responses compared using Kruskal Wallis test with Dunn’s
posttest. n=14d sham69, 1 mg MIA68, 2 mg MIA69. P,0.05 *, P,0.01, **). The sham and 2 mg data is included for comparison, but has previously
been published in a different form [19].
doi:10.1371/journal.pone.0033730.g006
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However, the existence of a robust non-inflammatory pain
behavioural phenotype at the 14d timepoint, which neither
exacerbates nor resolves over succeeding weeks [5], as well as
the well characterised spinal pharmacological plasticity at this
stage [18,19] justify the focus of the present study on this
timepoint.
Because of the strong ATF-3 signal in response to MIA in L4
and 5 DRG we studied the effects of this treatment on the
innervation of hindpaw skin, a major peripheral target of these
neurones. Quantification of intra-epidermal nerve fibre density
(IENFD) is a sensitive means of assessing injury to small fibres used
in both clinical practice [37] and animal models of toxic
neuropathies [46,47,48,49]. 14 days after intra-articular 2 mg
MIA treatment, there was a 38% reduction in IENF density of
hindpaw skin. In contrast, treatment with 1 mg MIA did not
reduce IENFD.
This reduction in IENFD is similar to that previously reported
in models of painful toxic neuropathies, for instance the 24–44%
reduction seen in paclitaxel- and vincristine- experimental painful
neuropathies [46]. There are broad similarities in the behavioural
and anatomical phenotypes in 2 mg intra-articular MIA and
experimental paclitaxel-neuropathy. Both share hindpaw mechan-
ical and cooling, but not thermal, hypersensitivity, despite IENF
loss, features common to many painful neuropathies [48,50].
Traumatic nerve injury models are associated with a response in
dorsal horn microglia, accompanied by subsequent astrocytosis,
which may contribute to the development and maintenance of
neuropathic pain [51,52,53]. In response to injury, microglia
proliferate [29,54,55], migrate to the site of injury [56,57] and
undergo a morphological change to become less ramified and
more amoeboid [58]. In terms of function, they can phagocytose
cellular debris [59], present antigens [60] and secrete a broad
range of cytokines and chemokines which amplify the transmission
of nociceptive information in the dorsal horn [51]. The induction
of microgliosis appears dependent on primary afferent electrical
activity, as well as numerous neuron-to-glia signalling molecules
including neuregulin-1, CCL2 and fractalkine [29]
Following 2 mg intra-articular MIA, we noted increased
numbers of ‘effector’ microglia within both the dorsal and ventral
horn. The 1 mg MIA treatment did not increase the total number
of microglia within the dorsal horn nor lead to a significant change
in their morphology. Previous studies have shown that the
microglial response within the dorsal horn is robustly evoked by
traumatic nerve injury but that certain models of chemotherapy-
evoked peripheral neuropathy [61] and most inflammatory pain
models [62,63] do not produce a microglial response, with some
exceptions [64]. This suggests that there may be a threshold of
stress or axonal injury that a neuron needs to achieve before
microglia can be recruited into a pro-inflammatory response, even
when a ‘dying back’ neuropathy of sensory neurones is present.
The presence of microglial activation at the 14d timepoint, while
inflammation resolves at the 7d timepoint [9], also suggests that
microglial activation in this case is not primarily linked to
inflammation
Numerous studies indicate that gabapentinoid drugs, such as
pregabalin, are significantly better able to modulate spinal innocuous
and nociceptive transmission in models of neuropathy or other pain
states than under physiological conditions [19,65,66]. This is
supported clinically by functional magnetic resonance imaging
evidence that gabapentin is significantly better able to modulate
nociceptive transmission following the induction of central sensitiza-
tion [21]. The ability of pregabalinto reduce deep dorsal horn evoked
responses significantly in the 2 mg MIA group, but not in 1 mg MIA
or sham treated animals, may thus indicate the presence of central
sensitization in the 2 mg group that is not present in the 1 mg
animals. This may account for the reduced behavioural hypersen-
sitivity to stimuli applied to the hindpaw referred-pain area in 1 mg
MIA treated animals compared to more sensitized 2 mg treated
group. Alternatively, the differential effect of pregabalin could reflect
the differing extents of peripheral neuronal injury in the 2 mg and
1 mg groups.
It should be noted that while the presence of central
sensitization is often found to be a necessary condition for
gabapentinoid efficacy, it is clearly not a sufficient condition.
Hence, although central sensitization may be present in some
other inflammatory chronic pain states, in the absence of
additional factors (such as the presence of neuropathy, or
activation of descending serotonergic facilitatory controls) gaba-
pentinoid efficacy does not increase [19,65].
Clinical studies suggest the existence of a subpopulation of OA
patients who experience pain with neuropathic features. In
patients undergoing surgical management of OA, pain often
persists after joint replacement [23]. A recent imaging study
reveals abnormal descending controls from brain to spinal cord in
a subgroup of patients with OA [24], an event seen in animal
neuropathic models as well as in the MIA model [19,25], with the
extent of this change correlating with patients’ use of neuropathic
pain descriptors. Coupled with the demonstration of increased
central sensitization and referred pain [67], these studies suggest
the existence of central changes in OA resembling those seen in
neuropathic pain.
Furthermore, in addition to reported cutaneous hypoaesthesia
with paradoxical mechanical allodynia overlying the degenerating
knee in OA patients, there is also loss of peripheral vibratory sense
distal to the degenerating knee in these patients, with the degree of
loss of acuity proportional to the radiographic OA severity
[68,69,70]. Whether this loss correlates to any alteration in IENF
in these distal territories clinically is currently unknown.
There is considerable variation in the dose and volume used
preclinically to induce the MIA model. Assessment of 43 studies
published to date indicates that 1, 2 and 3 mg MIA doses were in
equally common usage (Table S2). The available data suggests that
there are different pathophysiological sequellae that follow
different doses of MIA, with the 2 mg dose associated with a
much greater degree of neuronal injury and/or central sensitiza-
tion than 1 mg MIA. This includes a ‘dying back’ of small fibre
afferents innervating targets outside of the knee joint, which, if it
can be attributed to neurotoxicity, that would call into question the
utility of the 2 mg MIA model for translational study of
osteoarthritis pain. However, the concurrent neuropathic and
osteoarthritic phenotypes of the 2 mg MIA model, irrespective of
the etiology of the former, could still allow the use of this model to
investigate clinical osteoarthritic pain with neuropathic features/
descriptors
In summary, the divergent sequellae following different doses of
MIA must be taken into account when interpreting data generated
using the model, especially where indirect outcome measures of
joint pain have been employed and where doses greater than 1 mg
MIA are used.
Supporting Information
Figure S1 Spinal cord expression of ATF-3 following
2 mg MIA treatment. A - nuclear expression of ATF-3 in
magnocellular ventral horn ipsilateral to 2 mg MIA injection. B -
quantification of total ATF-3
+ nuclei/4 sections counted (one-way
ANOVA with Dunnett’s multiple comparison test, n=8 animals
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horn ATF-3 expression at day 7.
(TIF)
Figure S2 Analysis of peripheral nerve following 2 mg
MIA injection. A, B - toluidine-blue stained semithin sections of
common peroneal nerve ipsilateral (A) or contralateral (B) to 2 mg
MIA injection at day 7 of the model. There is no visible axon
degeneration, demyelination or inflammatory cell infiltrate (n=4
per group).
(TIF)
Table S1 Mean cartilage proteoglycan score for 2 mg
MIA, 1 mg MIA and saline injected joints, as assessed
using toluidine blue staining (See Fig. 1C, D.). Scoring
reflects the degree of proteoglycan loss, with 12 corresponding to
total loss over the entirety of both condylar surfaces, while 1 is
undisrupted cartilage proteoglycan. n=461 mg, 362 mg ani-
mals, +14d saline injected contralateral controls.
(DOC)
Table S2 43 published studies which used the MIA
model. Columns denote dose of monoiodoacetate used. The
highest dose was 4.8 mg, the lowest was 0.01 mg. Studies in bold
specifically assessed evoked pain responses at the hindpaw. Where
multiple doses were used, a study is referenced at each dose.
(DOC)
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